Update shared on 14 Nov 2025
Fair value Increased 6.15%Narrative Update on LivaNova Analyst Price Target
Analysts have raised their price target for LivaNova by $4, now valuing the company at $69.00. This update reflects revised models that take into account management’s updated 2025 outlook and improved revenue growth projections.
Analyst Commentary
Bullish Takeaways- Bullish analysts have raised the price target, which signals increased confidence in the company’s medium-term growth trajectory.
- Revisions to the company’s financial model reflect improved revenue forecasts, highlighting the execution of strategic initiatives and operational improvements.
- Positive sentiment is supported by management’s updated 2025 outlook. This suggests more robust performance ahead.
- The current valuation is viewed as supported by enhanced visibility into the growth strategy and ongoing business momentum.
- Despite the upward adjustment to the price target, some analysts maintain a neutral stance and cite lingering uncertainty in areas such as margin performance and competitive positioning.
- Analysts remain cautious about the company’s ability to fully realize management’s ambitious 2025 guidance and emphasize the need for continued operational discipline.
- Potential volatility tied to execution risks, particularly if growth assumptions do not materialize as expected, continues to be a point of concern.
What's in the News
- LivaNova raised its earnings guidance for full year 2025, increasing its organic revenue growth outlook by 50 basis points to a range of 9.5% to 10.5% (Key Developments).
- The company began the commercial launch of the Essenz Perfusion System in China after receiving regulatory approval. The system supports data-driven, patient-tailored perfusion for cardiopulmonary bypass procedures and is now available in several key global markets (Key Developments).
- LivaNova will present its strategic roadmap and growth pillars at an upcoming Analyst/Investor Day (Key Developments).
- Barclays raised its price target on LivaNova to $58, reflecting updated models based on management's latest outlook (Barclays, Periodical).
Valuation Changes
- The Fair Value Price Target has increased from $65 to $69.00, reflecting a higher consensus on the company's intrinsic value.
- The Discount Rate has risen slightly, moving from 8.31% to 8.56%, suggesting modestly higher perceived risk or cost of capital in updated models.
- Revenue Growth assumptions have been upgraded from 6.38% to 6.91%, indicating more optimistic expectations for top-line expansion.
- The Net Profit Margin estimate has declined modestly, down from 10.71% to 10.37%, reflecting slightly lower anticipated profitability.
- The Future P/E ratio forecast has increased from 26.90x to 28.41x, which may indicate a higher valuation multiple being assigned to projected earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.